Stock DNA
Pharmaceuticals & Biotechnology
CNY 7,860 Million (Mid Cap)
79.00
NA
0.53%
-0.41
4.22%
2.37
Revenue and Profits:
Net Sales:
277 Million
(Quarterly Results - Sep 2025)
Net Profit:
41 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.23%
0%
15.23%
6 Months
17.95%
0%
17.95%
1 Year
81.35%
0%
81.35%
2 Years
93.09%
0%
93.09%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Wuxi Unicomp Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
29.76%
EBIT Growth (5y)
-32.50%
EBIT to Interest (avg)
62.61
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.45
Sales to Capital Employed (avg)
0.21
Tax Ratio
12.65%
Dividend Payout Ratio
44.14%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.06%
ROE (avg)
3.01%
Valuation key factors
Factor
Value
P/E Ratio
79
Industry P/E
Price to Book Value
2.88
EV to EBIT
99.84
EV to EBITDA
71.79
EV to Capital Employed
4.33
EV to Sales
9.51
PEG Ratio
NA
Dividend Yield
0.43%
ROCE (Latest)
4.34%
ROE (Latest)
3.66%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
276.70
179.00
54.58%
Operating Profit (PBDIT) excl Other Income
31.10
15.90
95.60%
Interest
0.30
0.00
Exceptional Items
4.00
9.00
-55.56%
Consolidate Net Profit
41.50
28.20
47.16%
Operating Profit Margin (Excl OI)
112.50%
45.50%
6.70%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 54.58% vs 18.23% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 47.16% vs 8.05% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
736.40
585.50
25.77%
Operating Profit (PBDIT) excl Other Income
101.60
62.00
63.87%
Interest
0.50
0.40
25.00%
Exceptional Items
27.40
31.80
-13.84%
Consolidate Net Profit
143.30
114.20
25.48%
Operating Profit Margin (Excl OI)
98.00%
65.30%
3.27%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 25.77% vs 20.80% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 25.48% vs 59.27% in Dec 2023
About Wuxi Unicomp Technology Co., Ltd. 
Wuxi Unicomp Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






